Literature DB >> 19895837

Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

James A McCubrey1, Stephen L Abrams, Kristin Stadelman, William H Chappell, Michelle Lahair, Richard A Ferland, Linda S Steelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19895837      PMCID： PMC2862855          DOI： 10.1016/j.advenzreg.2009.10.016

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN： 0065-2571


× No keyword cloud information.
  170 in total

Review 1.  Signalling through the lipid products of phosphoinositide-3-OH kinase.

Authors:  A Toker; L C Cantley
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

2.  Early transplantation to a normal microenvironment prevents the development of Steel hematopoietic stem cell defects.

Authors:  J E Barker
Journal:  Exp Hematol       Date:  1997-06       Impact factor: 3.084

3.  Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases.

Authors:  R Marais; Y Light; H F Paterson; C S Mason; C J Marshall
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

4.  Differential inactivation of postsynaptic density-associated and soluble Ca2+/calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A.

Authors:  S Strack; M A Barban; B E Wadzinski; R J Colbran
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

5.  A signaling complex of Ca2+-calmodulin-dependent protein kinase IV and protein phosphatase 2A.

Authors:  R S Westphal; K A Anderson; A R Means; B E Wadzinski
Journal:  Science       Date:  1998-05-22       Impact factor: 47.728

6.  ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter.

Authors:  R S Thomas; M J Tymms; L H McKinlay; M F Shannon; A Seth; I Kola
Journal:  Oncogene       Date:  1997-06-12       Impact factor: 9.867

7.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Authors:  D Bonnet; J E Dick
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

8.  Identification of novel human tumor cell-specific CaMK-II variants.

Authors:  R M Tombes; G W Krystal
Journal:  Biochim Biophys Acta       Date:  1997-03-01

9.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Authors:  D R Alessi; S R James; C P Downes; A B Holmes; P R Gaffney; C B Reese; P Cohen
Journal:  Curr Biol       Date:  1997-04-01       Impact factor: 10.834

10.  Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells.

Authors:  S Xie; J E Price; M Luca; D Jean; Z Ronai; M Bar-Eli
Journal:  Oncogene       Date:  1997-10-23       Impact factor: 9.867
View more
  18 in total

Review 1.  GnRH signaling, the gonadotrope and endocrine control of fertility.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Mark S Roberson
Journal:  Front Neuroendocrinol       Date:  2010-05-06       Impact factor: 8.606

2.  Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer.

Authors:  Runbi Ji; Bin Zhang; Xu Zhang; Jianguo Xue; Xiao Yuan; Yongmin Yan; Mei Wang; Wei Zhu; Hui Qian; Wenrong Xu
Journal:  Cell Cycle       Date:  2015-06-19       Impact factor: 4.534

3.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

4.  The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; Ellis W T Wong; William H Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-10       Impact factor: 4.534

5.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

Review 6.  MicroRNAs targeting prostate cancer stem cells.

Authors:  Yu-Xiang Fang; Yun-Li Chang; Wei-Qiang Gao
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

Review 7.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Authors:  Linda S Steelman; William H Chappell; Stephen L Abrams; Ruth C Kempf; Jacquelyn Long; Piotr Laidler; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Franca Stivala; Maria C Mazzarino; Marco Donia; Paolo Fagone; Graziella Malaponte; Ferdinando Nicoletti; Massimo Libra; Michele Milella; Agostino Tafuri; Antonio Bonati; Jörg Bäsecke; Lucio Cocco; Camilla Evangelisti; Alberto M Martelli; Giuseppe Montalto; Melchiorre Cervello; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-03       Impact factor: 5.682

Review 8.  Soy isoflavones and prostate cancer: a review of molecular mechanisms.

Authors:  Abeer M Mahmoud; Wancai Yang; Maarten C Bosland
Journal:  J Steroid Biochem Mol Biol       Date:  2013-12-25       Impact factor: 4.292

Review 9.  Cancer stem cell theory: therapeutic implications for nanomedicine.

Authors:  Ke Wang; Xianguo Wu; Jianwei Wang; Jian Huang
Journal:  Int J Nanomedicine       Date:  2013-02-28

10.  Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.

Authors:  Shanmiao Gou; Pengfei Cui; Xiangsheng Li; Pengfei Shi; Tao Liu; Chunyou Wang
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.